FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169661194> ?p ?o ?g. }

• W2169661194 endingPage "991.e2" @default.
• W2169661194 startingPage "983" @default.
• W2169661194 abstract "BackgroundThe tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) has been implicated in immune suppression and tolerance induction.ObjectiveWe examined (1) whether IDO activity is required during tolerance induction by allergen immunotherapy or for the subsequent suppressive effects on asthma manifestations and (2) whether tryptophan depletion or generation of its downstream metabolites is involved.MethodsOvalbumin (OVA)–sensitized and OVA-challenged BALB/c mice that display increased airway responsiveness to methacholine, serum OVA-specific IgE levels, bronchoalveolar eosinophilia, and TH2 cytokine levels were used as a model of allergic asthma. Sensitized mice received subcutaneous optimal (1 mg) or suboptimal (100 μg) OVA immunotherapy.ResultsInhibition of IDO by 1-methyl-DL-tryptophan during immunotherapy, but not during inhalation challenge, partially reversed the suppressive effects of immunotherapy on airway eosinophilia and TH2 cytokine levels, whereas airway hyperresponsiveness and serum OVA-specific IgE levels remained suppressed. Administration of tryptophan during immunotherapy failed to abrogate its beneficial effects toward allergic airway inflammation. Interestingly, administration of tryptophan or its metabolites, kynurenine, 3-hydroxykynurenine, and xanthurenic acid, but not 3-hydroxyanthranilinic acid, quinolinic acid, and kynurenic acid, during suboptimal immunotherapy potentiated the reduction of eosinophilia. These effects coincided with reduced TH2 cytokine levels in bronchoalveolar lavage fluid, but no effects on IgE levels were detected.ConclusionDuring immunotherapy, the tryptophan metabolites kynurenine, 3-hydroxykynurenine, and xanthurenic acid generated through IDO contribute to tolerance induction regarding TH2-dependent allergic airway inflammation. The tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) has been implicated in immune suppression and tolerance induction. We examined (1) whether IDO activity is required during tolerance induction by allergen immunotherapy or for the subsequent suppressive effects on asthma manifestations and (2) whether tryptophan depletion or generation of its downstream metabolites is involved. Ovalbumin (OVA)–sensitized and OVA-challenged BALB/c mice that display increased airway responsiveness to methacholine, serum OVA-specific IgE levels, bronchoalveolar eosinophilia, and TH2 cytokine levels were used as a model of allergic asthma. Sensitized mice received subcutaneous optimal (1 mg) or suboptimal (100 μg) OVA immunotherapy. Inhibition of IDO by 1-methyl-DL-tryptophan during immunotherapy, but not during inhalation challenge, partially reversed the suppressive effects of immunotherapy on airway eosinophilia and TH2 cytokine levels, whereas airway hyperresponsiveness and serum OVA-specific IgE levels remained suppressed. Administration of tryptophan during immunotherapy failed to abrogate its beneficial effects toward allergic airway inflammation. Interestingly, administration of tryptophan or its metabolites, kynurenine, 3-hydroxykynurenine, and xanthurenic acid, but not 3-hydroxyanthranilinic acid, quinolinic acid, and kynurenic acid, during suboptimal immunotherapy potentiated the reduction of eosinophilia. These effects coincided with reduced TH2 cytokine levels in bronchoalveolar lavage fluid, but no effects on IgE levels were detected. During immunotherapy, the tryptophan metabolites kynurenine, 3-hydroxykynurenine, and xanthurenic acid generated through IDO contribute to tolerance induction regarding TH2-dependent allergic airway inflammation." @default.
• W2169661194 created "2016-06-24" @default.
• W2169661194 creator A5039260766 @default.
• W2169661194 creator A5045478952 @default.
• W2169661194 creator A5051707428 @default.
• W2169661194 creator A5052236122 @default.
• W2169661194 creator A5058742094 @default.
• W2169661194 creator A5072582857 @default.
• W2169661194 creator A5072654925 @default.
• W2169661194 creator A5081546550 @default.
• W2169661194 date "2008-04-01" @default.
• W2169661194 modified "2023-10-06" @default.
• W2169661194 title "Indoleamine 2,3-dioxygenase–dependent tryptophan metabolites contribute to tolerance induction during allergen immunotherapy in a mouse model" @default.
• W2169661194 cites W1507248048 @default.
• W2169661194 cites W1532147512 @default.
• W2169661194 cites W1554937135 @default.
• W2169661194 cites W1605075022 @default.
• W2169661194 cites W1677467555 @default.
• W2169661194 cites W175676769 @default.
• W2169661194 cites W1967404929 @default.
• W2169661194 cites W1967755721 @default.
• W2169661194 cites W1976640573 @default.
• W2169661194 cites W1977831876 @default.
• W2169661194 cites W1981906652 @default.
• W2169661194 cites W1985517826 @default.
• W2169661194 cites W1996087599 @default.
• W2169661194 cites W2014141569 @default.
• W2169661194 cites W2015260577 @default.
• W2169661194 cites W2025603553 @default.
• W2169661194 cites W2033232206 @default.
• W2169661194 cites W2037920661 @default.
• W2169661194 cites W2046678045 @default.
• W2169661194 cites W2057001364 @default.
• W2169661194 cites W2068471769 @default.
• W2169661194 cites W2069362757 @default.
• W2169661194 cites W2075875408 @default.
• W2169661194 cites W2098403531 @default.
• W2169661194 cites W2103092316 @default.
• W2169661194 cites W2108838739 @default.
• W2169661194 cites W2119939110 @default.
• W2169661194 cites W2122285073 @default.
• W2169661194 cites W2123812720 @default.
• W2169661194 cites W2123993941 @default.
• W2169661194 cites W2125865438 @default.
• W2169661194 cites W2131135525 @default.
• W2169661194 cites W2140881278 @default.
• W2169661194 cites W2141725341 @default.
• W2169661194 cites W2144724673 @default.
• W2169661194 cites W2146914242 @default.
• W2169661194 cites W2148044949 @default.
• W2169661194 cites W2159749046 @default.
• W2169661194 cites W2167897482 @default.
• W2169661194 cites W2332203063 @default.
• W2169661194 cites W2337282311 @default.
• W2169661194 cites W3100493246 @default.
• W2169661194 doi "https://doi.org/10.1016/j.jaci.2007.11.021" @default.
• W2169661194 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18179817" @default.
• W2169661194 hasPublicationYear "2008" @default.
• W2169661194 type Work @default.
• W2169661194 sameAs 2169661194 @default.
• W2169661194 citedByCount "69" @default.
• W2169661194 countsByYear W21696611942012 @default.
• W2169661194 countsByYear W21696611942013 @default.
• W2169661194 countsByYear W21696611942014 @default.
• W2169661194 countsByYear W21696611942015 @default.
• W2169661194 countsByYear W21696611942016 @default.
• W2169661194 countsByYear W21696611942017 @default.
• W2169661194 countsByYear W21696611942018 @default.
• W2169661194 countsByYear W21696611942020 @default.
• W2169661194 countsByYear W21696611942021 @default.
• W2169661194 countsByYear W21696611942022 @default.
• W2169661194 countsByYear W21696611942023 @default.
• W2169661194 crossrefType "journal-article" @default.
• W2169661194 hasAuthorship W2169661194A5039260766 @default.
• W2169661194 hasAuthorship W2169661194A5045478952 @default.
• W2169661194 hasAuthorship W2169661194A5051707428 @default.
• W2169661194 hasAuthorship W2169661194A5052236122 @default.
• W2169661194 hasAuthorship W2169661194A5058742094 @default.
• W2169661194 hasAuthorship W2169661194A5072582857 @default.
• W2169661194 hasAuthorship W2169661194A5072654925 @default.
• W2169661194 hasAuthorship W2169661194A5081546550 @default.
• W2169661194 hasConcept C141105273 @default.
• W2169661194 hasConcept C159654299 @default.
• W2169661194 hasConcept C203014093 @default.
• W2169661194 hasConcept C2776042228 @default.
• W2169661194 hasConcept C2776706248 @default.
• W2169661194 hasConcept C2776710720 @default.
• W2169661194 hasConcept C2777037409 @default.
• W2169661194 hasConcept C2777129736 @default.
• W2169661194 hasConcept C2777503454 @default.
• W2169661194 hasConcept C2777701055 @default.
• W2169661194 hasConcept C2777702733 @default.
• W2169661194 hasConcept C2777896816 @default.
• W2169661194 hasConcept C2778690821 @default.
• W2169661194 hasConcept C2779187253 @default.
• W2169661194 hasConcept C2909466502 @default.
• W2169661194 hasConcept C515207424 @default.
• W2169661194 hasConcept C55493867 @default.

• next